Ranbaxy Laboratories Ltd (RANB.BO)

RANB.BO on Bombay Stock Exchange

859.90INR
1 Apr 2015
Change (% chg)

-- (--)
Prev Close
Rs859.90
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
0
52-wk High
Rs869.00
52-wk Low
Rs519.95

RANB.BO

Chart for RANB.BO

About

Ranbaxy Laboratories Limited (Ranbaxy) is a research-based international pharmaceutical company serving customers in over 150 countries. The Company develops, manufactures and markets generic, branded generic, value-added and over-the-counter (OTC) products, anti-retrovirals (ARVs), active pharmaceutical ingredients (APIs) and... (more)

Overall

Beta: 0.44
Market Cap(Mil.): Rs365,985.50
Shares Outstanding(Mil.): 425.66
Dividend: --
Yield (%): --

Financials

  RANB.BO Industry Sector
P/E (TTM): -- 35.83 39.81
EPS (TTM): -19.13 -- --
ROI: -- 17.03 16.23
ROE: -- 17.93 17.36
Search Stocks

BUZZ-India's Sun Pharma rises; Credit Suisse says Ranbaxy drug prices hiked

** Company hikes prices in unit Ranbaxy Laboratories' US-branded portfolio - Credit Suisse

30 Jun 2015

BUZZ-India's Sun Pharma slumps as much as 10 pct on Q4 results

** Sun Pharmaceutical Industries slumps as much as 10 pct to 869.10 rupees as of 0445 GMT, its lowest since Feb. 27

01 Jun 2015

Sun Pharma misses profit estimates on Ranbaxy costs

MUMBAI - Sun Pharmaceutical Industries Ltd, India's largest drugmaker by sales, reported fourth-quarter profit well below analysts' expectations, hit by costs related to integrating smaller rival Ranbaxy Laboratories Ltd.

29 May 2015

India's Sun Pharma misses profit estimates on Ranbaxy costs

MUMBAI, May 29 - Sun Pharmaceutical Industries Ltd , India's largest drugmaker by sales, reported fourth-quarter profit well below analysts' expectations, hit by costs related to integrating smaller rival Ranbaxy Laboratories Ltd.

29 May 2015

U.S. class action asserts India's Ranbaxy manipulated FDA rules

MUMBAI - Indian generic drugmaker Ranbaxy Laboratories Ltd has been sued in a district court in the United States for allegedly manipulating U.S. Food and Drug Administration rules for years to keep rival generic drugs out of the market.

14 May 2015

U.S. class action asserts Ranbaxy manipulated FDA rules

MUMBAI - Generic drugmaker Ranbaxy Laboratories Ltd has been sued in a district court in the United States for allegedly manipulating U.S. Food and Drug Administration rules for years to keep rival generic drugs out of the market.

14 May 2015

U.S. class action asserts India's Ranbaxy manipulated FDA rules

MUMBAI, May 14 - Indian generic drugmaker Ranbaxy Laboratories Ltd has been sued in a district court in the United States for allegedly manipulating U.S. Food and Drug Administration rules for years to keep rival generic drugs out of the market.

14 May 2015

Sun Pharma, not sated by Ranbaxy deal, may spend up to $7 billion on M&A - bankers

MUMBAI - Sun Pharmaceuticals Industries Ltd , emboldened by its takeover of domestic rival Ranbaxy Laboratories, is willing to spend as much as $7 billion on further acquisitions, bankers familiar with the generic drugmaker's strategy said.

28 Apr 2015

DEALTALK-Sun Pharma, not sated by Ranbaxy deal, may spend up to $7 bln on M&A -bankers

* Sun Pharma looking to buy overseas biosimilar assets - bankers

28 Apr 2015

BUZZ-Japan's Daiichi Sankyo gains on stake sale in Sun Pharma

** Daiichi Sankyo Co Ltd shares rise 2.6 pct after the company said it was selling a part or all of its stake in Indian drugmaker Sun Pharmaceutical Industries Ltd

21 Apr 2015

Earnings vs. Estimates

Search Stocks